Skip to Main Content
Try STAT+ TODAY
Trending:
Health
Biotech
STAT+
First Opinion
The Readout

A wild ride for Alnylam stock & sympathy for the pharma CEO

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Sept. 21, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for September 21, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Lured by a bigger payday, a medical device maker…
Lured by a bigger payday, a medical device maker sold fake plastic parts. Many were implanted…
Tired of ‘dead end’ approach, herpes patients mobilize to…
Tired of ‘dead end’ approach, herpes patients mobilize to demand government action
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories